Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Rhea-AI Summary
Heartflow (Nasdaq: HTFL), a leader in AI-powered coronary artery disease technology, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET.
Investors can access both live and archived versions of the presentation through Heartflow's Investor Relations website at ir.heartflow.com.
Positive
- None.
Negative
- None.
News Market Reaction – HTFL
On the day this news was published, HTFL declined 7.54%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.8% during that session. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $240M from the company's valuation, bringing the market cap to $2.94B at that time.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET.
A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide. Discover how we’re shaping the future of cardiovascular care at www.heartflow.com.
Investor Contact
Nick Laudico
nlaudico@heartflow.com
Media Contact
Elliot Levy
elevy@heartflow.com
FAQ
When is Heartflow (HTFL) presenting at the Morgan Stanley Healthcare Conference 2025?
Where can I watch Heartflow's Morgan Stanley Conference presentation?
What is Heartflow's (HTFL) main business focus?
What type of presentation will Heartflow give at the Morgan Stanley Healthcare Conference?
